<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        56-44-12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ECALTA 100MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ANIDULAFUNGIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        612.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PHARMACIA UPJOHN" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PHARMACIA UPJOHN
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J02AX06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ECALTA contains the active substance anidulafungin and is prescribed in adults and in paediatric patients aged 1 month to less than 18 years to treat a type of fungal infection of the blood or other internal organs called invasive candidiasis. The infection is caused by fungal cells (yeasts) called <em>Candida</em>.</p><p>&nbsp;</p><p>ECALTA belongs to a group of medicines called echinocandins. These medicines are used to treat serious fungal infections.</p><p>&nbsp;</p><p>ECALTA prevents normal development of fungal cell walls. In the presence of ECALTA, fungal cells have incomplete or defective cell walls, making them fragile or unable to grow.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use ECALTA</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to anidulafungin, other echinocandins (e.g. caspofungin acetate), or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p>Warnings and precautions</p><p>&nbsp;</p><p>Talk to your doctor or pharmacist or nurse before using ECALTA.</p><p>&nbsp;</p><p>Your doctor may decide to monitor you</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for liver function more closely if you develop liver problems during your treatment</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are given anaesthetics during your treatment with ECALTA for signs of an allergic reaction such as itching, wheezing, blotchy skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for signs of an infusion&ndash;related reaction which could include a rash, hives, itching, redness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for shortness of breath/breathing difficulties, dizziness or lightheadedness</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p><strong>&nbsp;</strong></p><p>ECALTA should not be given to patients under 1 month of age.</p><p><strong>&nbsp;</strong></p><p>Other medicines and ECALTA</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you or your child are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>&nbsp;</p><p>The effect of ECALTA in pregnant women is not known. Therefore ECALTA is not recommended during pregnancy. Effective contraception should be used in women of childbearing age. Contact your doctor immediately if you become pregnant while taking ECALTA.</p><p>&nbsp;</p><p>The effect of ECALTA in breast-feeding women is not known. Ask your doctor or pharmacist for advice before taking ECALTA while breast-feeding.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking any medicines.</p><p><strong>&nbsp;</strong></p><p><strong>ECALTA contains fructose</strong></p><p><strong>&nbsp;</strong></p><p>This medicine contains fructose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>&nbsp;</p><p>If you (or your child) have hereditary fructose intolerance (HFI), a rare genetic disorder, you (or your child) must not receive this medicine. Patients with HFI cannot break down fructose in this medicine, which may cause serious side effects.</p><p>&nbsp;</p><p>You must tell your doctor before receiving this medicine if you (or your child) have HFI or if your child can no longer take sweet foods or drinks because they feel sick, vomit or get unpleasant effects such as bloating, stomach cramps or diarrhoea.</p><p>&nbsp;</p><p><strong>ECALTA contains sodium</strong></p><p><strong>&nbsp;</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ECALTA will always be prepared and given to you or your child by a doctor or a healthcare professional (there is more information about the method of preparation at the end of the leaflet in the section for medical and healthcare professionals only).</p><p>&nbsp;</p><p>For use in adults, the treatment starts with 200&nbsp;mg on the first day (loading dose). This will be followed by a daily dose of 100&nbsp;mg (maintenance dose).&nbsp;</p><p>&nbsp;</p><p>For use in children and adolescents (age from 1 month to less than 18 years), the treatment starts with 3.0&nbsp;mg/kg (not to exceed 200&nbsp;mg) on the first day (loading dose). This will be followed by a daily dose of 1.5&nbsp;mg/kg (not to exceed 100&nbsp;mg) (maintenance dose). The dose that is given depends on the patient&rsquo;s weight.</p><p>&nbsp;</p><p>ECALTA should be given to you once a day, by slow infusion (a drip) into your vein. For adults, this will take at least <u>1.5 hours for the maintenance dose and 3 hours for the loading dose.</u> For children and adolescents, the infusion may take less time depending on the patient&rsquo;s weight.</p><p>&nbsp;</p><p>Your doctor will determine the duration of your treatment and how much ECALTA you will receive each day and will monitor your response and condition.</p><p>&nbsp;</p><p>In general, your treatment should continue for at least 14&nbsp;days after the last day <em>Candida</em> was found in your blood.</p><p>&nbsp;</p><p>If you receive more ECALTA than you should</p><p>&nbsp;</p><p>If you are concerned that you may have been given too much ECALTA, tell your doctor or another healthcare professional immediately.</p><p>&nbsp;</p><p><strong>If you forgot to use ECALTA</strong></p><p><strong>&nbsp;</strong></p><p>As you will be given this medicine under close medical supervision, it is unlikely that a dose would be missed. However tell your doctor or pharmacist if you think that a dose has been forgotten.</p><p>&nbsp;</p><p>You should not be given a double dose by doctor.</p><p>&nbsp;</p><p><strong>If you stop using ECALTA</strong></p><p><strong>&nbsp;</strong></p><p>You should not experience any effects from ECALTA if your doctor stops ECALTA treatment.</p><p>&nbsp;</p><p>Your doctor may prescribe another medicine following your treatment with ECALTA to continue treating your fungal infection or prevent it from returning.</p><p>&nbsp;</p><p>If your original symptoms come back, tell your doctor or another healthcare professional immediately.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, or pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Some of these side effects will be noted by your doctor while monitoring your response and condition.<br />&nbsp;</p><p>Life-threatening allergic reactions that might include difficulty breathing with wheezing or worsening of an existing rash have been rarely reported during administration of ECALTA.</p><p><strong>&nbsp;</strong></p><p><strong>Serious side effects &ndash; tell your doctor or another healthcare professional immediately should any of the following occur:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsion (seizure)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, pruritis (itching)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hot flush</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden contraction of the muscles around the airways resulting in wheezing or coughing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty of breathing</p><p><strong>&nbsp;</strong></p><p><strong>Other side effects</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very common side effects (may affect more than 1 in 10 people) are: </strong></p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood potassium (hypokalaemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p><strong>&nbsp;</strong></p><p><strong>Common side effects (may affect up to 1 in 10 people) are:</strong></p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsion (seizure)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in blood tests of liver function</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, pruritis (itching)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in blood tests of kidney function</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal flow of bile from the gallbladder into the intestine<strong> </strong>(cholestasis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood sugar</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden contraction of the muscles around the airways resulting in wheezing or coughing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty of breathing</p><p>&nbsp;</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people) are:</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disorder of blood clotting system</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hot flush</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain at injection site</p><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data) are:</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Life-threatening allergic reactions</p><p>&nbsp;</p><p><strong>Reporting of side effects </strong></p><p>If you get any side effects, talk to your doctor or, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>&nbsp;</p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre ( NPC )</p><p>&middot;&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext 2317-2356-2340</p><p>&middot;&nbsp;&nbsp; Call center : 19999</p><p>&middot;&nbsp;&nbsp; Fax: +966 11 205 7662</p><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website :https://ade.sfda.gov.sa/&nbsp;&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label. The expiry data refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p><p>&nbsp;</p><p>The reconstituted solution may be stored up to 25&deg;C for up to 24 hours. The infusion solution may be stored at 25&deg;C (room temperature) for 48 hours (do not freeze) and should be administered at 25&deg;C (room temperature) within 48 hours.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is anidulafungin. Each vial of powder contains 100&nbsp;mg anidulafungin.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: fructose (see section 2 &ldquo;ECALTA contains fructose&rdquo;), mannitol, polysorbate 80, tartaric acid, sodium hydroxide (for pH-adjustment) (see section 2 &ldquo;ECLATA contains sodium&rdquo;), hydrochloric acid (for pH-adjustment)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	ECALTA is supplied as a box containing 1 vial of 100 mg powder for concentrate for solution for infusion.
	
	The powder is white to off-white.  

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Pfizer Manufacturing Belgium NV, Belgium</p><p>&nbsp;</p><p><strong>Manufactured By:</strong></p><p>Pharmacia Upjohn Company LLC, United States</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي إيكالتا على مادة فعالة وهي الأنيدولافونجين ويوصف لمعالجة البالغين والمرضى من الأطفال بعمر شهر واحد إلى أقل من ۱۸ عامًا من أحد أنواع العدوى الفطرية التي تصيب الدم أو غيره من الأعضاء الداخلية وتسمى هذه العدوى بالمبيضات الغازية. وتُسبب هذه العدوى الخلايا الفطرية (الخمائر) التي يطلق عليها المبْيَضَّاتِ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينتمي عقار إيكالتا إلى مجموعة العقاقير التي يطلق عليها الايكينوكاندينات. وتُستخدم هذه العقاقير في علاج العداوى الفطرية الشديدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمنع دواء إيكالتا التطور الطبيعي لجدران الخلايا الفطرية. عند تواجد دواء إيكالتا تكون جدران الخلايا الفطرية غير مكتملة أو معيبة مما يجعلها ضعيفة أو غير قادرة على النمو.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال إيكالتا</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية تجاه أنيدولافونجين أو أيٍ من العقاقير من فئة الايكينوكاندينات (مثل أسيتات كاسبوفونجين) أو تجاه أي مكون آخر من مكونات هذا العقار (المدرجة في القسم ٦).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاحتياطات عند استعمال إيكالتا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل استخدام إيكالتا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ربما يقرر طبيبك مراقبتك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للتحقق من وظائف الكبد عن كثب إذا تطورت لديك مشكلات الكبد أثناء فترة علاجك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول مسكنات عند معالجتك بإيكالتا، تحسبًا لظهور علامات تفاعل حساسية مثل الحكة، الأزيز، ظهور بقع على الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحسبًا لظهور علامات التفاعل المتعلق بالتنقيط التي قد تتضمن الطفح الجلدي، الشرى، الحكة، الاحمرار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحسبًا للإصابة بضيق التنفس/صعوبة التنفس، أو الدوار، أو الدوخة</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يوصف عقار إيكالتا للمرضى الذين يقل عمرهم عن شهر واحد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب إخطار الطبيب أو الصيدلاني إذا كنت أنت أو طفلك تتناولان أو تناولتما مؤخرًا أو قد تتناولان أي أدوية أخرى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إن تأثير دواء إيكالتا على النساء الحوامل غير معروف؛ لذا لا يوصى باستخدام إيكالتا أثناء الحمل. يجب على النساء في عمر الإنجاب استخدام عقاقير فعالة لمنع الحمل. اتصلي بطبيبك فورًا إذا أصبحتِ حاملًا أثناء تناولك لدواء إيكالتا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن تأثير دواء إيكالتا على النساء المرضعات رضاعة طبيعية غير معروف. اطلبي النصيحة من طبيبك أو من الصيدلاني قبل تناول دواء إيكالتا إذا كنت مُرضعًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اطلبي النصيحة من طبيبك أو من الصيدلاني قبل تناول أي دواء.</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات إيكالتا</strong></p><p dir="RTL"><strong>يحتوي إيكالتا على الفركتوز </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على الفركتوز (وهو نوع من أنواع السكر). إذا أخبرك طبيبك أنك لا تستطيع تحمل بعض السكريات، فاتصل به قبل تناول هذا المنتج الدوائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت أنت (أو طفلك) تعاني من عدم التحمل الوراثي للفركتوز (HFI)، وهو اضطراب جيني نادر، يجب ألا تتلقى أنت (أو طفلك) هذا الدواء. لا يستطيع المرضى المصابون بعدم التحمل الوراثي للفركتوز أن يقوموا بتكسير الفركتوز الموجود في هذا الدواء، مما قد يسبب آثارًا جانبية خطيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تخبر طبيبك قبل تلقي هذا الدواء إذا كنت أنت (أو طفلك) تعاني من عدم التحمل الوراثي للفركتوز أو إذا كان طفلك لم يعد بإمكانه تناول أطعمة أو مشروبات سكرية لأنه يصاب بالغثيان، أو القيء، أو يصاب بأعراض مزعجة مثل الانتفاخ، أو تقلصات المعدة، أو الإسهال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي </strong><strong>إيكالتا </strong><strong>على الصوديوم</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من واحد مليمول من الصوديوم (۲۳ ملجم) لكل قارورة، وهذا يعني أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سوف يقوم الطبيب أو مقدم الرعاية الصحية بإعداد حقنة إيكالتا وإعطائها لك أنت أو طفلك (يوجد المزيد من المعلومات حول طريقة التحضير في نهاية النشرة في القسم المُخصص للأطباء ومقدمي الرعاية الصحية فقط).</p><p dir="RTL">&nbsp;</p><p dir="RTL">للاستخدام مع البالغين، يبدأ العلاج بجرعة ۲۰۰&nbsp;ملجم في اليوم الأول (جرعة التحميل). تتبعها جرعة ۱۰۰ ملجم يوميًا (جرعات الثبات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">للاستخدام مع الأطفال والمراهقين (الذين تتراوح أعمارهم بين شهر واحد وأقل من ۱۸ عامًا)، يبدأ العلاج بجرعة قدرها 3.0 ملجم/كلجم (ولا تزيد عن ۲۰۰ ملجم) في اليوم الأول (جرعة التحميل). تتبعها جرعة يومية قدرها 1.5 ملجم/كلجم (ولا تزيد عن ۱۰۰ ملجم) (جرعة الثبات). وتعتمد الجرعة التي يتم إعطاؤها على وزن المريض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب إعطاء دواء إيكالتا مرة واحدة يوميًا عن طريق التنقيط البطيء في الوريد. بالنسبة للبالغين، يستغرق ذلك <u>على الأقل 1,5 ساعة لجرعة الثبات و</u><u>۳</u><u> ساعات لجرعة التحميل. </u>بالنسبة للأطفال والمراهقين، قد يستغرق التنقيط وقتًا أقل اعتمادًا على وزن المريض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يحدد الطبيب فترة العلاج وكمية دواء إيكالتا اليومية وسيراقب استجابتك وحالتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بشكلٍ عام، يجب أن يستمر علاجك لمدة ۱٤ يومًا على الأقل تبدأ بعد آخر يوم لاكتشاف المبْيَضَّاتِ في دمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من إيكالتا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تشعر بالقلق من احتمال تناولك كمية كبيرة من دواء إيكالتا فاخبر طبيبك أو مقدم الرعاية الصحية على الفور.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>نسيان تناول جرعة إيكالتا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">بما أن هذا الدواء سوف يُعطى لك تحت إشراف طبي، لذا من غير المرجح أن تفوتك جرعة ما. مع ذلك أخبر طبيبك أو الصيدلاني إذا كنت تعتقد أنك قمت بتفويت جرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ألَّا يعطيك الطبيب جرعة مضاعفة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التوقف عن تناول إيكالتا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يجب أن تظهر عليك أي آثار إذا قام الطبيب بإيقاف العلاج بإيكالتا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يصف لك الطبيب دواءً آخر بعد انتهاء العلاج باستخدام إيكالتا لاستمرار العلاج من عدوى الفطريات أو لمنع عودتها مرة أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا عادت الأعراض الرئيسية مرة أخرى فقم بإبلاغ الطبيب أو مقدم الرعاية الصحية على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وإذا كانت لديك المزيد من الأسئلة بشأن استخدام هذا الدواء، فاطرحها على الطبيب أو الصيدلاني أو الممرضة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، قد يسبب هذا الدواء آثارًا جانبية، بالرغم من عدم تعرض الجميع لها. سيُلاحظ طبيبك ظهور بعض من هذه الآثار الجانبية أثناء مراقبته لاستجابتك ولحالتك.</p><p dir="RTL">قلما تم الإبلاغ عن تفاعلات الحساسية المهددة للحياة والتي قد تتضمن صعوبة التنفس المصحوب بصفير أو تفاقم حالة طفح جلدي موجودة بالفعل أثناء إعطاء إيكالتا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية الخطيرة &ndash; أخبر طبيبك أو أي أخصائي رعاية صحية فورًا في حال حدوث أي مما يلي:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; التشنج (نوبات تشنجية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; احمرار الوجه (هبّات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي وحكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الاحمرار الشديد للوجه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الشرى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; تقلص مفاجئ في العضلات حول المسالك الهوائية مما يؤدي إلى أزيز عند التنفس أو سعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الأخرى</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الشائعة للغاية (التي قد تصيب أكثر من فرد واحد بين كل </strong><strong>۱۰</strong><strong> أفراد) هي:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى البوتاسيوم بالدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة (التي قد تصيب ما يصل إلى فرد واحد بين كل </strong>۱۰<strong> أفراد) هي: </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنج (نوبات تشنجية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في فحوصات الدم الخاصة بوظائف الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي وحكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في فحوصات الدم الخاصة بوظائف الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التدفق غير الطبيعي للعصارة الصفراوية من المرارة إلى الأمعاء (الركود الصفراوي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى السكر بالدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلص مفاجئ في العضلات حول المسالك الهوائية مما يؤدي إلى الأزيز أو السعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأعراض الجانبية غير الشائعة (التي قد تصيب ما يصل إلى فرد واحد بين كل </strong>۱۰۰<strong> فرد) هي:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب نظام تجلط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الوجه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاحمرار الشديد للوجه مع سخونة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم بموضع الحقن</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية غير المعروفة (لا يمكن تقييم تكرار حدوثها من خلال البيانات المتاحة) هي:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية المهددة للحياة</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الممرضة أو الصيدلي إذا لاحظت أي أمر يجعلك تشعر أنك لست على ما يرام.</p><p dir="RTL">قد تحدث أيضًا مع بعض الأشخاص آثار جانبية أخرى غير مدرجة أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تستغرق فوائد <strong>إيكالتا</strong> اوآثاره الجانبية بعض الوقت لكي تظهر. ولهذا، فحتى بعد أن تنتهي فترة تلقيك للعلاج، ينبغي أن تخبر طبيبك فورًا إذا لاحظت أيًا من الآثار الجانبية المدرجة في هذا القسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي بشأنها. يتضمن ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><ul><li dir="RTL">المملكة العربية السعودية</li></ul><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ الدوائي (NPC)</p><ul><li dir="RTL">الاتصال بالمركز الوطني للتيقظ والسلامة الدوائية: ۰۰۹٦٦۱۱۲۰۳۸۲۲۲، تحويلة: ٢٣١٧-٢٣٥٦-٢٣٤٠</li><li dir="RTL">الاتصال بالمركز: ۱۹۹۹۹</li><li dir="RTL">الفاكس: ۹۹٦٦۱۱۲۰٥٧٦٦۲+</li><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa/</li></ul><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>&nbsp;&nbsp; </u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><strong>دول الخليج الأخرى</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>الرجاء</em><em> </em><em>الاتصال</em><em> </em><em>بالمؤسسات</em><em> </em><em>والهيئات</em><em> </em><em>الوطنية</em><em> </em><em>في</em><em> </em><em>كل</em><em> </em><em>دولة.</em></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد انتهاء فترة الصلاحية المُبينة على الملصق. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ في الثلاجة (درجتين مئويتين &ndash; ۸ درجات مئوية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب تخزين المحلول المعاد تحضيره في درجة حرارة بين ۲ و۲٥ درجة مئوية لمدة تصل إلى ساعة. لا تجمد الدواء.</p><p dir="RTL">يجب حفظ محلول التنقيط في ثلاجة (۲ - ۸ &deg; درجة مئوية) (لا تقم بتجميد الدواء) ويجب إعطاؤها عند درجة حرارة ۲٥ درجة مئوية (درجة حرارة الغرفة) خلال ۲٤ ساعة. لا تقم بتجميد الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم التخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- المادة الفعالة هي الأنيدولافونجين. تحتوي كل قارورة مسحوق على ۱۰۰&nbsp;ملجم من الأنيدولافونجين.</p><p dir="RTL">- المكونات الأخرى هي: فركتوز (انظر القسم ۲ &quot;يحتوي إيكالتا على الفركتوز&quot;) ومانيتول وبوليسوربات ۸۰ وحمض التارتاريك وهيدروكسيد الصوديوم (لمعادلة الحمض) (انظر القسم ۲ &quot;يحتوي إيكالتا على الصوديوم&quot;) وحمض الهيدروكلوريك (لمعادلة الحمض)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم توفير إيكالتا في صورة علبة بها قارورة واحدة تحتوي على ۱۰۰&nbsp;ملجم من المسحوق المركز لتحضير محلول للتنقيط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لون المسحوق أبيض أو أبيض مائل إلى الصُفرة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المسوقة:</strong></p><p dir="RTL">Pfizer Manufacturing Belgium NV, Belgium</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المصنع:</strong></p><p dir="RTL">Pharmacia Upjohn Company LLC, United States</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أكتوبر/تشرين الأول ۲۰۲۰
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ECALTA 100 mg powder for concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 100 mg anidulafungin.
The reconstituted solution contains 3.33 mg/mL anidulafungin and the diluted solution contains 0.77 mg/mL anidulafungin.

Excipient with known effect: ECALTA contains fructose.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion. 
White to off-white lyophilised solid. 
The reconstituted solution has a pH of 3.5 to 5.5. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of invasive candidiasis in adults and paediatric patients aged 1&nbsp;month to &lt;&nbsp;18 years (see sections 4.4 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with ECALTA should be initiated by a physician experienced in the management of invasive fungal infections.<strong><em> </em></strong></p><p><u>&nbsp;</u></p><p><u>Posology</u></p><p><u>&nbsp;</u></p><p>Specimens for fungal culture should be obtained prior to therapy. Therapy may be initiated before culture results are known and can be adjusted accordingly once they are available.</p><p>&nbsp;</p><p><em>Adult population (dosing and treatment duration)</em></p><p>A single 200&nbsp;mg loading dose should be administered on Day 1, followed by&nbsp;100&nbsp;mg daily thereafter. Duration of treatment should be based on the patient&rsquo;s clinical response.</p><p><strong>&nbsp;</strong></p><p>In general, antifungal therapy should continue for at least 14&nbsp;days after the last positive culture.</p><p><em>&nbsp;</em></p><p>There are insufficient data to support the 100&nbsp;mg dose for longer than 35 days of treatment.</p><p>&nbsp;</p><p><em>Patients with renal and hepatic impairment</em></p><p>No dosing adjustments are required for patients with mild, moderate, or severe hepatic impairment. No dosing adjustments are required for patients with any degree of renal insufficiency, including those on dialysis. ECALTA can be given without regard to the timing of haemodialysis (see section 5.2).</p><p>&nbsp;</p><p><em>Other special populations</em></p><p>No dosing adjustments are required for adult patients based on gender, weight, ethnicity, HIV positivity, or elderly (see section 5.2).</p><p>&nbsp;</p><p><em>Paediatric population (1 month to &lt;&nbsp;18 years) (dosing and treatment duration)</em></p><p>A single loading dose of 3.0&nbsp;mg/kg (not to exceed 200&nbsp;mg) should be administered on Day 1 followed by a daily maintenance dose of 1.5&nbsp;mg/kg (not to exceed 100&nbsp;mg) thereafter.</p><p>&nbsp;</p><p>Duration of treatment should be based on the patient&rsquo;s clinical response.</p><p><strong>&nbsp;</strong></p><p>In general, antifungal therapy should continue for at least 14&nbsp;days after the last positive culture.</p><p><u>&nbsp;</u></p><p>The safety and efficacy of ECALTA have not been established in neonates (&lt;&nbsp;1 month old) (see section 4.4).</p><p><strong>&nbsp;</strong></p><p><u>Method of administration </u></p><p><u>&nbsp;</u></p><p>For intravenous use only.</p><p>&nbsp;</p><p>ECALTA should be reconstituted with water for injection to a concentration of 3.33&nbsp;mg/mL and subsequently diluted to a concentration of 0.77&nbsp;mg/mL for the final infusion solution. For a paediatric patient, the volume of infusion solution required to deliver the dose will vary depending on the weight of the child. For instructions on reconstitution of the medicinal product before administration (see section 6.6).</p><p>&nbsp;</p><p>It is recommended that ECALTA be administered at a rate of infusion that does not exceed 1.1&nbsp;mg/min (equivalent to 1.4&nbsp;mL/min when reconstituted and diluted per instructions). Infusion associated reactions are infrequent when the rate of anidulafungin infusion does not exceed 1.1&nbsp;mg/min (see section 4.4).</p><p>&nbsp;</p><p>ECALTA must not be administered as a bolus injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 

Hypersensitivity to other medicinal products of the echinocandin class.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ECALTA has not been studied in patients with <em>Candida</em> endocarditis, osteomyelitis or meningitis.</p><p>&nbsp;</p><p>The efficacy of ECALTA has only been evaluated in a limited number of neutropenic patients (see section 5.1).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>Treatment with ECALTA in neonates (&lt;&nbsp;1 month old) is not recommended. Treating neonates requires consideration for coverage of disseminated candidiasis including central nervous system (CNS); nonclinical infection models indicate that higher doses of anidulafungin are needed to achieve adequate CNS penetration (see section 5.3), resulting in higher doses of polysorbate 80, a formulation excipient. High doses of polysorbates have been associated with potentially life-threatening toxicities in neonates as reported in the literature.</p><p>&nbsp;</p><p><strong><u>There is no clinical data to support the efficacy and safety of higher doses of anidulafungin than recommended in 4.2.</u></strong></p><p>&nbsp;</p><p><u>Hepatic effects</u></p><p>&nbsp;</p><p>Increased levels of hepatic enzymes have been seen in healthy subjects and patients treated with anidulafungin. In some patients with serious underlying medical conditions who were receiving multiple concomitant medicines along with anidulafungin, clinically significant hepatic abnormalities have occurred. Cases of significant hepatic dysfunction, hepatitis, and hepatic failure were uncommon in clinical trials. Patients with increased hepatic enzymes during anidulafungin therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing anidulafungin therapy.</p><p>&nbsp;</p><p><u>Anaphylactic reactions</u></p><p><u>&nbsp;</u></p><p>Anaphylactic reactions, including shock, were reported with the use of anidulafungin. If these reactions occur, anidulafungin should be discontinued and appropriate treatment administered.</p><p>&nbsp;</p><p><u>Infusion-related reactions</u></p><p><u>&nbsp;</u></p><p>Infusion-related adverse events have been reported with anidulafungin, including rash, urticaria, flushing, pruritus, dyspnoea, bronchospasm and hypotension. Infusion-related adverse events are infrequent when the rate of anidulafungin infusion does not exceed 1.1&nbsp;mg/min (see section 4.8).</p><p>&nbsp;</p><p>Exacerbation of infusion-related reactions by co-administration of anaesthetics has been seen in a non-clinical (rat) study (see section 5.3). The clinical relevance of this is unknown. Nevertheless, care should be taken when co-administering anidulafungin and anaesthetic agents.</p><p>&nbsp;</p><p><u>Fructose content</u></p><p><u>&nbsp;</u></p><p><u>ECALTA contains fructose</u></p><p><u>&nbsp;</u></p><p>Patients with hereditary fructose intolerance (HFI) should not be given this medicine unless strictly necessary.</p><p>&nbsp;</p><p>Babies and young children (below 2&nbsp;years of age) may not yet be diagnosed with HFI. Medicines (containing fructose) given intravenously may be life‑threatening and should not be administered in this population unless there is an overwhelming clinical need and no alternatives are available.</p><p>&nbsp;</p><p>A detailed history with regard to HFI symptoms has to be taken of each patient prior to being given this medicinal product.</p><p>&nbsp;</p><p><u>Sodium content</u></p><p><u>&nbsp;</u></p><p>ECALTA contains less than 1 mmol sodium (23 mg) per vial. Patients on low sodium diets can be informed that this medicinal product is essentially &lsquo;sodium‑free&rsquo;.</p><p><u>&nbsp;</u></p><p>ECALTA may be diluted with sodium-containing solutions (see section 6.6) and this should be considered in relation to the total sodium from all sources that will be administered to the patient.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 isoenzymes (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A). Of note, <em>in vitro</em> studies do not fully exclude possible <em>in vivo</em> interactions.</p><p>&nbsp;</p><p>Drug interaction studies were performed with anidulafungin and other medicinal products likely to be co-administered. No dosage adjustment of either medicinal product is recommended when anidulafungin is co-administered with ciclosporin, voriconazole or tacrolimus, and no dosage adjustment for anidulafungin is recommended when co-administered with amphotericin B or rifampicin.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p>There are no data from the use of anidulafungin in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>&nbsp;</p><p>ECALTA is not recommended during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><u>&nbsp;</u></p><p>It is unknown whether anidulafungin is excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of anidulafungin in milk.</p><p>&nbsp;</p><p>A risk to the suckling child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ECALTA therapy taking into account the benefit of breast‑feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>For anidulafungin, there were no effects on fertility in studies conducted in male and female rats (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p>Infusion-related adverse reactions have been reported with anidulafungin in clinical studies, including rash, pruritus, dyspnoea, bronchospasm, hypotension (common events), flushing, hot flush, and urticaria (uncommon events), summarized in Table 1 (see section 4.4).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>The following table includes, the all-causality adverse reactions (MedDRA terms) from 840 subjects receiving 100&nbsp;mg anidulafungin with frequency corresponding to very common (&ge;1/10), common (&sup3;1/100 to &lt;1/10), uncommon (&sup3;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000) and from spontaneous reports with frequency not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="7" style="vertical-align:top"><p>Table 1. Table of Adverse Reactions</p></td></tr><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Very Common</p><p>&ge; 1/10</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p><p>&ge; 1/100</p><p>to</p><p>&lt; 1/10</p></td><td style="vertical-align:top"><p>Uncommon</p><p>&ge; 1/1000</p><p>&nbsp;to</p><p>&lt;1/100</p></td><td style="vertical-align:top"><p>Rare</p><p>&ge; 1/10,000 to</p><p>&lt;1/1,000</p></td><td style="vertical-align:top"><p>Very Rare</p><p>&lt; 1/10,000</p></td><td style="vertical-align:top"><p>Not Known</p><p>&nbsp;</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Blood and Lymphatic System Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td><td style="vertical-align:top"><p>Coagulopathy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune System Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic shock, anaphylactic reaction*</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and Nutrition Disorders</p></td><td style="vertical-align:top"><p>Hypokalaemia</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous System Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Convulsion,</p><p>headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension,</p><p>hypertension</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Flushing,</p><p>hot flush</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, Thoracic and Mediastinal Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bronchospasm,</p><p>Dyspnoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal Disorders</p></td><td style="vertical-align:top"><p>Diarrhoea,</p><p>Nausea</p></td><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Abdominal pain upper</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased,</p><p>blood alkaline phosphatase increased,</p><p>aspartate aminotransferase increased, blood bilirubin increased,</p><p>cholestasis</p></td><td style="vertical-align:top"><p>Gamma-glutamyltransferase increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and Subcutaneous Tissue Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash,</p><p>pruritus</p></td><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and Urinary Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General Disorders and Administration Site Conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Infusion site pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* See section 4.4.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The safety of anidulafungin was investigated in 68 paediatric patients (1 month to &lt;&nbsp;18 years) with ICC in a prospective, open-label, non-comparative paediatric study (see section 5.1). The frequencies of certain hepatobiliary adverse events, including alanine aminotransferase (ALT) increased and aspartate aminotransferase (AST) increased appeared at a higher frequency (7-10%) in these paediatric patients than has been observed in adults (2%). Although chance or differences in underlying disease severity may have contributed, it cannot be excluded that hepatobiliary adverse reactions occur more frequently in paediatric patients compared to adults.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after<u> marketing</u> authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions <u>according to their local country requirements.</u></p><p><u>&nbsp;</u></p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website:https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with any overdose, general supportive measures should be utilised as necessary. In case of overdose, adverse reactions may occur as mentioned in section 4.8.</p><p>&nbsp;</p><p>During clinical trials, a single 400&nbsp;mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse reactions were reported. No dose limiting toxicity was observed in a study of 10 healthy subjects administered a loading dose of 260&nbsp;mg followed by 130&nbsp;mg daily; 3 of the 10 subjects experienced transient, asymptomatic transaminase elevations (&pound;&nbsp;3 x Upper Limit of Normal (ULN)).</p><p>&nbsp;</p><p>During a paediatric clinical trial, one subject received two doses of anidulafungin that were 143% of the expected dose. No clinical adverse reactions were reported.</p><p>&nbsp;</p><p>ECALTA is not dialysable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group:&nbsp; &ndash; Antimycotics for systemic use, other antimycotics for systemic use. ATC code: JO2AX06</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p><u>&nbsp;</u></p><p>Anidulafungin is a semi-synthetic echinocandin, a lipopeptide synthesised from a fermentation product of <em>Aspergillus nidulans</em>.</p><p>&nbsp;</p><p>Anidulafungin selectively inhibits 1,3-&beta;-D glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3-b-D-glucan, an essential component of the fungal cell wall. Anidulafungin has shown fungicidal activity against <em>Candida</em> species and activity against regions of active cell growth of the hyphae of <em>Aspergillus fumigatus</em>.</p><p>&nbsp;</p><p><u>Activity<em> in vitro</em></u></p><p><em>&nbsp;</em></p><p>Anidulafungin exhibited <em>in-vitro </em>activity against <em>C. albicans, C. glabrata, C. parapsilosis, C. krusei </em>and <em>C. tropicalis. </em>For the clinical relevance of these findings see &ldquo;Clinical efficacy and safety.&rdquo;</p><p>&nbsp;</p><p>Isolates with mutations in the hot spot regions of the target gene have been associated with clinical failures or breakthrough infections. Most clinical cases involve caspofungin treatment. However, in animal experiments these mutations confer cross resistance to all three echinocandins and therefore such isolates are classified as echinocandin resistant until further clinical experience are obtained concerning anidulafungin.</p><p>&nbsp;</p><p>The<em> in vitro</em> activity of anidulafungin against <em>Candida </em>species is not uniform. Specifically, for <em>C. parapsilosis, </em>the MICs of anidulafungin are higher than are those of other <em>Candida</em> species. A standardized technique for testing the susceptibility of <em>Candida</em> species to anidulafungin as well as the respective interpretative breakpoints has been established by European Committee on Antimicrobial Susceptibility Testing (EUCAST).</p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3" style="vertical-align:top"><p><u>Table 2.</u><u> </u><u>EUCAST Breakpoints</u></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em><u>Candida</u></em><u> Species</u></p></td><td colspan="2" style="vertical-align:top"><p><u>MIC breakpoint (mg/L)</u></p></td></tr><tr><td style="vertical-align:top"><p>&le;S (Susceptible)</p></td><td style="vertical-align:top"><p>&gt;R (Resistant)</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida albicans</em></p></td><td style="vertical-align:top"><p>0.03</p></td><td style="vertical-align:top"><p>0.03</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida glabrata</em></p></td><td style="vertical-align:top"><p>0.06</p></td><td style="vertical-align:top"><p>0.06</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida tropicalis</em></p></td><td style="vertical-align:top"><p>0.06</p></td><td style="vertical-align:top"><p>0.06</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida krusei</em></p></td><td style="vertical-align:top"><p>0.06</p></td><td style="vertical-align:top"><p>0.06</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida parapsilosis</em></p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p><em>Other Candida spp.</em><sup>1</sup></p></td><td colspan="2" style="vertical-align:top"><p>Insufficient evidence</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><sup>1</sup></strong> Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific <em>Candida</em> species. They are for use only for organisms that do not have specific breakpoints</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Activity<em> in vivo</em></u></p><p><em><u>&nbsp;</u></em></p><p>Parenterally administered anidulafungin was effective against <em>Candida</em> species in immunocompetent and immunocompromised mouse and rabbit models. Anidulafungin treatment prolonged survival and also reduced the organ burden of <em>Candida</em> species, when determined at intervals from 24 to 96 hours after the last treatment.</p><p>&nbsp;</p><p>Experimental infections included disseminated <em>C. albicans</em> infection in neutropenic rabbits, oesophageal/oropharyngeal infection of neutropenic rabbits with fluconazole-resistant <em>C. albicans</em> and disseminated infection of neutropenic mice with fluconazole-resistant <em>C. glabrata.</em></p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em>Candidaemia and other forms of Invasive Candidiasis</em></p><p>The safety and efficacy of anidulafungin were evaluated in a pivotal Phase 3, randomised, double-blind, multicentre, multinational study of primarily non-neutropenic patients with candidaemia and a limited number of patients with deep tissue <em>Candida</em> infections or with abscess-forming disease. Patients with <em>Candida</em> endocarditis, osteomyelitis or meningitis, or those with infection due to <em>C.&nbsp;krusei</em>, were specifically excluded from the study. Patients were randomised to receive either anidulafungin (200&nbsp;mg intravenous loading dose followed by 100&nbsp;mg intravenous daily) or fluconazole (800&nbsp;mg intravenous loading dose followed by 400&nbsp;mg intravenous daily), and were stratified by APACHE II score (&le;20 and &gt;20) and the presence or absence of neutropenia. Treatment was administered for at least 14 and not more than 42 days. Patients in both study arms were permitted to switch to oral fluconazole after at least 10 days of intravenous therapy, provided that they were able to tolerate oral medicinal products and were afebrile for at least 24 hours, and that the most recent blood cultures were negative for <em>Candida</em> species.</p><p>&nbsp;</p><p>Patients who received at least one dose of study medicinal products and who had a positive culture for <em>Candida</em> species from a normally sterile site before study entry were included in the modified intent-to-treat (MITT) population. In the primary efficacy analysis, global response in the MITT populations at the end of intravenous therapy, anidulafungin was compared to fluconazole in a pre-specified two-step statistical comparison (non-inferiority followed by superiority). A successful global response required clinical improvement and microbiological eradication. Patients were followed for six weeks beyond the end of all therapy.</p><p>&nbsp;</p><p>Two hundred and fifty-six patients, ranging from 16 to 91 years in age, were randomised to treatment and received at least one dose of study medication. The most frequent species isolated at baseline were <em>C. albicans</em> (63.8% anidulafungin, 59.3% fluconazole), followed by <em>C. glabrata</em> (15.7%, 25.4%), <em>C.&nbsp;parapsilosis</em> (10.2%, 13.6%) and <em>C. tropicalis</em> (11.8%, 9.3%) &ndash; with 20, 13 and 15 isolates of the last 3 species, respectively, in the anidulafungin group. The majority of patients had Apache II scores &le; 20 and very few were neutropenic.</p><p>&nbsp;</p><p>Efficacy data, both overall and by various subgroups, are presented below in Table 3.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p>Table 3. Global success in the MITT population: primary and secondary endpoints</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anidulafungin<br />&nbsp;</p></td><td style="vertical-align:top"><p>Fluconazole<br />&nbsp;</p></td><td style="vertical-align:top"><p>Between group difference<sup> a</sup></p><p>(95% CI)</p></td></tr><tr><td style="vertical-align:top"><p><strong>End of IV Therapy (1&ordm; endpoint)</strong></p></td><td style="vertical-align:top"><p><strong>96/127 (75.6%)</strong></p></td><td style="vertical-align:top"><p><strong>71/118 (60.2%)</strong></p></td><td style="vertical-align:top"><p><strong>15.42 (3.9, 27.0)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Candidaemia only</p></td><td style="vertical-align:top"><p>88/116 (75.9%)</p></td><td style="vertical-align:top"><p>63/103 (61.2%)</p></td><td style="vertical-align:top"><p>14.7 (2.5, 26.9)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Other sterile sites<sup>b</sup></p></td><td style="vertical-align:top"><p>8/11 (72.7%)</p></td><td style="vertical-align:top"><p>8/15 (53.3%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peritoneal fluid/IA<sup>c</sup> abscess</p></td><td style="vertical-align:top"><p>6/8</p></td><td style="vertical-align:top"><p>5/8</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other</p></td><td style="vertical-align:top"><p>2/3</p></td><td style="vertical-align:top"><p>3/7</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; <em>C. albicans</em><sup>d</sup></p></td><td style="vertical-align:top"><p>60/74 (81.1%)</p></td><td style="vertical-align:top"><p>38/61 (62.3%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Non-<em>albicans</em> species<sup>d</sup></p></td><td style="vertical-align:top"><p>32/45 (71.1%)</p></td><td style="vertical-align:top"><p>27/45 (60.0%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Apache II score &le; 20</p></td><td style="vertical-align:top"><p>82/101 (81.2%)</p></td><td style="vertical-align:top"><p>60/98 (61.2%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Apache II score &gt; 20</p></td><td style="vertical-align:top"><p>14/26 (53.8%)</p></td><td style="vertical-align:top"><p>11/20 (55.0%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Non-neutropenic <strong>(ANC, cells/mm<sup>3</sup> </strong><strong>&gt;</strong><strong> 500)</strong></p></td><td style="vertical-align:top"><p>94/124 (75.8%)</p></td><td style="vertical-align:top"><p>69/114 (60.5%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Neutropenic <strong>(ANC, cells/mm<sup>3 </sup>&le; 500)</strong></p></td><td style="vertical-align:top"><p>2/3</p></td><td style="vertical-align:top"><p>2/4</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>At Other Endpoints</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; End of All Therapy</p></td><td style="vertical-align:top"><p>94/127 (74.0%)</p></td><td style="vertical-align:top"><p>67/118 (56.8%)</p></td><td style="vertical-align:top"><p>17.24 (2.9, 31.6)<sup>e</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; 2 Week Follow-up</p></td><td style="vertical-align:top"><p>82/127 (64.6%)</p></td><td style="vertical-align:top"><p>58/118 (49.2%)</p></td><td style="vertical-align:top"><p>15.41 (0.4, 30.4)<sup>e</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; 6 Week Follow-up</p></td><td style="vertical-align:top"><p>71/127 (55.9%)</p></td><td style="vertical-align:top"><p>52/118 (44.1%)</p></td><td style="vertical-align:top"><p>11.84 (-3.4, 27.0)<sup>e</sup></p></td></tr></tbody></table><p><sup>a</sup> Calculated as anidulafungin minus fluconazole</p><p><sup>b </sup>With or without concurrent candidaemia</p><p><sup>c </sup>Intra-abdominal</p><p><sup>d</sup> Data presented for patients with a single baseline pathogen.</p><p><sup>e </sup>98.3% confidence intervals, adjusted post hoc for multiple comparisons of secondary time points.</p><p>&nbsp;</p><p>Mortality rates in both the anidulafungin and fluconazole arms are presented below in Table 4:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 4. Mortality</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anidulafungin<br />&nbsp;</p></td><td style="vertical-align:top"><p>Fluconazole<br />&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall study mortality</strong></p></td><td style="vertical-align:top"><p><strong>29/127 (22.8%)</strong></p></td><td style="vertical-align:top"><p><strong>37/118 (31.4%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mortality during study therapy</p></td><td style="vertical-align:top"><p>10/127 (7.9%)</p></td><td style="vertical-align:top"><p>17/118 (14.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Mortality attributed to <em>Candida</em> infection</p></td><td style="vertical-align:top"><p>2/127 (1.6%)</p></td><td style="vertical-align:top"><p>5/118 (4.2%)</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Additional Data in Neutropenic Patients </strong></p><p><strong>&nbsp;</strong></p><p>The efficacy of anidulafungin (200 mg intravenous loading dose followed by 100 mg intravenous daily) in adult neutropenic patients (defined as absolute neutrophil count &le; 500 cells/mm<sup>3</sup>, WBC &le; 500 cells/mm<sup>3 </sup>or classified by the investigator as neutropenic at baseline) with microbiologically confirmed invasive candidiasis was assessed in an analysis of pooled data from 5 prospective studies (1 comparative versus caspofungin and 4 open-label, non-comparative). Patients were treated for at least 14 days. In clinically stable patients, a switch to oral azole therapy was permitted after at least 5 to 10 days of treatment with anidulafungin. A total of 46 patients were included in the analysis. The majority of patients had candidaemia only (84.8%; 39/46). The most common pathogens isolated at baseline were <em>C. tropicalis</em> (34.8%; 16/46), <em>C. krusei</em> (19.6%; 9/46), <em>C. parapsilosis</em> (17.4%; 8/46), <em>C. albicans </em>(15.2%; 7/46), and <em>C. glabrata</em> (15.2%; 7/46). The successful global response rate at End of Intravenous Treatment (primary endpoint) was 26/46 (56.5%) and End of All Treatment was 24/46 (52.2%). All-cause mortality up to the end of the study (6 Week Follow-up Visit) was 21/46 (45.7%).</p><p>&nbsp;</p><p>The efficacy of anidulafungin in adult neutropenic patients (defined as absolute neutrophil count &le; 500&nbsp;cells/mm<sup>3</sup> at baseline) with invasive candidiasis was assessed in a prospective, double-blind, randomized, controlled trial. Eligible patients received either anidulafungin (200 mg intravenous loading dose followed by 100&nbsp;mg intravenous daily) or caspofungin (70 mg intravenous loading dose followed by 50 mg intravenous daily) (2:1 randomization). Patients were treated for at least 14 days. In clinically stable patients, a switch to oral azole therapy was permitted after at least 10 days of study treatment. A total of 14 neutropenic patients with microbiologically confirmed invasive candidiasis (MITT population) were enrolled in the study (11 anidulafungin; 3 caspofungin). The majority of patients had candidaemia only. The most common pathogens isolated at baseline were <em>C. tropicalis </em>(4&nbsp;anidulafungin, 0 caspofungin), <em>C. parapsilosi</em>s (2 anidulafungin, 1 caspofungin), <em>C. krusei</em> (2&nbsp;anidulafungin, 1 caspofungin), and <em>C. ciferrii</em> (2 anidulafungin, 0 caspofungin). The successful global response rate at the End of Intravenous Treatment (primary endpoint) was 8/11 (72.7%) for anidulafungin and 3/3 (100.0%) for caspofungin (difference -27.3, 95% CI -80.9, 40.3); the successful global response rate at the End of All Treatment was 8/11 (72.7%) for anidulafungin and 3/3 (100.0%) for caspofungin (difference -27.3, 95% CI -80.9, 40.3). All-cause mortality up to the 6 Week Follow-Up visit for anidulafungin (MITT population) was 4/11 (36.4%) and 2/3 (66.7%) for caspofungin.</p><p>&nbsp;</p><p>Patients with microbiologically confirmed invasive candidiasis (MITT population) and neutropenia were identified in an analysis of pooled data from 4 similarly designed prospective, open-label, non-comparative studies. The efficacy of anidulafungin (200 mg intravenous loading dose followed by 100&nbsp;mg intravenous daily) was assessed in 35 adult neutropenic patients defined as absolute neutrophil count &le; 500 cells/mm<sup>3</sup> or WBC &le; 500 cells/mm<sup>3</sup> in 22 patients or classified by the investigator as neutropenic at baseline in 13 patients. All patients were treated for at least 14 days. In clinically stable patients, a switch to oral azole therapy was permitted after at least 5 to 10 days of treatment with anidulafungin. The majority of patients had candidaemia only (85.7%). The most common pathogens isolated at baseline were <em>C. tropicalis</em> (12 patients), <em>C. albicans</em> (7 patients), <em>C. glabrata </em>(7 patients), <em>C. krusei </em>(7 patients), and <em>C. parapsilosis</em> (6 patients). The successful global response rate at the End of Intravenous Treatment (primary endpoint) was 18/35 (51.4%) and 16/35 (45.7%) at the End of All Treatment. All-cause mortality by Day 28 was 10/35 (28.6%). The successful global response rate at End of Intravenous Treatment and End of All Treatment were both 7/13 (53.8%) in the 13 patients with neutropenia assessed by investigators at baseline.</p><p><strong>&nbsp;</strong></p><p><strong>Additional Data in Patients with Deep Tissue Infections</strong></p><p><strong>&nbsp;</strong></p><p>The efficacy of anidulafungin (200 mg intravenous loading dose followed by 100 mg intravenous daily) in adult patients with microbiologically confirmed deep tissue candidiasis was assessed in an analysis of pooled data from 5 prospective studies (1 comparative and 4 open-label).&nbsp;Patients were treated for at least 14 days.&nbsp;In the 4 open-label studies, a switch to oral azole therapy was permitted after at least 5 to 10 days of treatment with anidulafungin.&nbsp;A total of 129 patients were included in the analysis.&nbsp;Twenty one (16.3%) had concomitant candidaemia.&nbsp;The mean APACHE II score was 14.9 (range, 2 &ndash; 44).&nbsp;The most common sites of infection included the peritoneal cavity (54.3%; 70 of 129), hepatobiliary tract (7.0%; 9 of 129), pleural cavity (5.4%; 7 of 129) and kidney (3.1%; 4 of 129).&nbsp;The most common pathogens isolated from a deep tissue site at baseline were <em>C. albicans</em> (64.3%; 83 of 129), <em>C. glabrata</em> (31.0%; 40 of 129), <em>C. tropicalis</em> (11.6%; 15 of 129), and <em>C. krusei</em> (5.4%; 7 of 129).&nbsp;The successful global response rate at the end of intravenous treatment (primary endpoint) and end of all treatment and all-cause mortality up to the 6 week follow-up visit is shown in Table 5.&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Table 5.&nbsp;&nbsp; Rate of Successful Global Response<sup>a</sup> and All-Cause Mortality in Patients with Deep Tissue Candidiasis &ndash; Pooled Analysis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>MITT Population</p><p>n/N (%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Global Response of Success at EOIVT<sup>b</sup></strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Overall</p></td><td style="vertical-align:top"><p>102/129 (79.1)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peritoneal cavity</p></td><td style="vertical-align:top"><p>51/70 (72.9)&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatobiliary tract</p></td><td style="vertical-align:top"><p>7/9 (77.8)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pleural cavity</p></td><td style="vertical-align:top"><p>6/7 (85.7)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney</p></td><td style="vertical-align:top"><p>3/4 (75.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Global Response of Success at EOT<sup>b</sup></strong></p></td><td style="vertical-align:top"><p>94/129 (72.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>All-Cause Mortality </strong></p></td><td style="vertical-align:top"><p>40/129 (31.0)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>a</sup> A successful global response was defined as both clinical and microbiologic success</p><p><sup>b</sup> EOIVT, End of Intravenous Treatment; EOT, End of All Treatment</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>A prospective, open-label, non-comparative, multi-national study assessed the safety and efficacy of anidulafungin in 68 paediatric patients aged 1 month to &lt;&nbsp;18 years with invasive candidiasis including candidaemia (ICC). Patients were stratified by age (1 month to &lt;&nbsp;2&nbsp;years, 2 to &lt;&nbsp;5 years, and 5 to &lt;&nbsp;18&nbsp;years) and received once daily intravenous anidulafungin (3.0&nbsp;mg/kg loading dose on Day 1, and 1.5&nbsp;mg/kg daily maintenance dose thereafter) for up to 35&nbsp;days followed by an optional switch to oral fluconazole (6-12&nbsp;mg/kg/day, maximum 800&nbsp;mg/day). Patients were followed at 2 and 6 weeks after EOT.</p><p>Among 68 patients who received anidulafungin, 64 had microbiologically confirmed <em>Candida</em> infection and were evaluated for efficacy in the modified intent-to-treat (MITT) population. Overall, 61 patients (92.2%) had <em>Candida</em> isolated from blood only. The most commonly isolated pathogens were <em>Candida albicans</em> (25 [39.1%] patients), followed by <em>Candida parapsilosis</em> (17 [26.6%] patients), and <em>Candida tropicalis</em> (9 [14.1%] patients). A successful global response was defined as having both a clinical response of success (cure or improvement) and a microbiological response of success (eradication or presumed eradication). The overall rates of successful global response in the MITT population are presented in Table 6.</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>Table 6. Summary of Successful Global Response by Age Group, MITT Population</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Successful Global Response, n (%)</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Timepoint</strong></p></td><td style="vertical-align:top"><p><strong>Global Response</strong></p></td><td style="vertical-align:top"><p><strong>1 month to &lt;&nbsp;2 years</strong></p><p><strong>(N=16)</strong></p><p><strong>n (n/N, %)</strong></p></td><td style="vertical-align:top"><p><strong>2 to &lt;&nbsp;5 years</strong></p><p><strong>(N=18)</strong></p><p><strong>n (n/N, %)</strong></p></td><td style="vertical-align:top"><p><strong>5 to &lt;&nbsp;18 years<br />(N=30)</strong></p><p><strong>n (n/N, %)</strong></p></td><td style="vertical-align:top"><p><strong>Overall</strong></p><p><strong>(N=64)<br />n (n/N, %)</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>EOIVT</strong></p></td><td colspan="2" style="vertical-align:top"><p>Success</p></td><td style="vertical-align:top"><p>11 (68.8)</p></td><td style="vertical-align:top"><p>14 (77.8)</p></td><td style="vertical-align:top"><p>20 (66.7)</p></td><td style="vertical-align:top"><p>45 (70.3)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>(41.3, 89.0)</p></td><td style="vertical-align:top"><p>(52.4, 93.6)</p></td><td style="vertical-align:top"><p>(47.2, 82.7)</p></td><td style="vertical-align:top"><p>(57.6, 81.1)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>EOT</strong></p></td><td colspan="2" style="vertical-align:top"><p>Success</p></td><td style="vertical-align:top"><p>11 (68.8)</p></td><td style="vertical-align:top"><p>14 (77.8)</p></td><td style="vertical-align:top"><p>21 (70.0)</p></td><td style="vertical-align:top"><p>46 (71.9)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>(41.3, 89.0)</p></td><td style="vertical-align:top"><p>(52.4, 93.6)</p></td><td style="vertical-align:top"><p>(50.6, 85.3)</p></td><td style="vertical-align:top"><p>(59.2, 82.4)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>2-week FU</strong></p></td><td colspan="2" style="vertical-align:top"><p>Success</p></td><td style="vertical-align:top"><p>11 (68.8)</p></td><td style="vertical-align:top"><p>13 (72.2)</p></td><td style="vertical-align:top"><p>22 (73.3)</p></td><td style="vertical-align:top"><p>46 (71.9)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>(41.3, 89.0)</p></td><td style="vertical-align:top"><p>(46.5, 90.3)</p></td><td style="vertical-align:top"><p>(54.1, 87.7)</p></td><td style="vertical-align:top"><p>(59.2, 82.4)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>6-week FU</strong></p></td><td colspan="2" style="vertical-align:top"><p>Success</p></td><td style="vertical-align:top"><p>11 (68.8)</p></td><td style="vertical-align:top"><p>12 (66.7)</p></td><td style="vertical-align:top"><p>20 (66.7)</p></td><td style="vertical-align:top"><p>43 (67.2)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>(41.3, 89.0)</p></td><td style="vertical-align:top"><p>(41.0, 86.7)</p></td><td style="vertical-align:top"><p>(47.2, 82.7)</p></td><td style="vertical-align:top"><p>(54.3, 78.4)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>95% CI = exact 95% confidence interval for binomial proportions using Clopper-Pearson method; EOIVT = End of Intravenous Treatment; EOT = End of All Treatment; FU = follow-up; MITT = modified intent-to-treat; N = number of subjects in the population; n = number of subjects with responses</p><p>&nbsp;</p><p><strong>Pharmacokinetic properties</strong></p><p>&nbsp;</p><p><u>General pharmacokinetic characteristics </u></p><p><u>&nbsp;</u></p><p>The pharmacokinetics of anidulafungin have been characterised in healthy subjects, special populations and patients. A low intersubject variability in systemic exposure (coefficient of variation ~25%) was observed. The steady state was achieved on the first day after a loading dose (twice the daily maintenance dose).</p><p>&nbsp;</p><p><u>Distribution</u></p><p><br />The pharmacokinetics of anidulafungin are characterised by a rapid distribution half-life (0.5-1 hour) and a volume of distribution, 30-50&nbsp;l, which is similar to total body fluid volume. Anidulafungin is extensively bound (&gt;99%) to human plasma proteins. No specific tissue distribution studies of anidulafungin have been done in humans. Therefore, no information is available about the penetration of anidulafungin into the cerebrospinal fluid (CSF) and/or across the blood-brain barrier.&nbsp;</p><p>&nbsp;</p><p><u>Biotransformation </u></p><p><u>&nbsp;</u></p><p>Hepatic metabolism of anidulafungin has not been observed. Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 isoenzymes. It is unlikely that anidulafungin will have clinically relevant effects on the metabolism of drugs metabolised by cytochrome P450 isoenzymes.</p><p>&nbsp;</p><p>Anidulafungin undergoes slow chemical degradation at physiologic temperature and pH to a ring-opened peptide that lacks antifungal activity. The <em>in vitro</em> degradation half-life of anidulafungin under physiologic conditions is approximately 24 hours. <em>In vivo</em>, the ring-opened product is subsequently converted to peptidic degradants and eliminated mainly through biliary excretion.</p><p>&nbsp;</p><p><u>Elimination</u></p><p><br />The clearance of anidulafungin is about 1&nbsp;l/h. Anidulafungin has a predominant elimination half-life of approximately 24 hours that characterizes the majority of the plasma concentration-time profile, and a terminal half-life of 40-50 hours that characterises the terminal elimination phase of the profile.</p><p>&nbsp;</p><p>In a single-dose clinical study, radiolabeled (<sup>14</sup>C)<strong> </strong>anidulafungin (~88&nbsp;mg) was administered to healthy subjects. Approximately 30% of the administered radioactive dose was eliminated in the faeces over 9 days, of which less than 10% was intact drug. Less than 1% of the administered radioactive dose was excreted in the urine, indicating negligible renal clearance. Anidulafungin concentrations fell below the lower limits of quantitation 6 days post-dose. Negligible amounts of drug-derived radioactivity were recovered in blood, urine, and faeces 8 weeks post-dose.</p><p>&nbsp;</p><p><u>Linearity</u></p><p><br />Anidulafungin displays linear pharmacokinetics across a wide range of once daily doses (15-130&nbsp;mg).</p><p>&nbsp;</p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p><em>Patients with fungal infections&nbsp; </em></p><p>The pharmacokinetics of anidulafungin in patients with fungal infections are similar to those observed in healthy subjects based on population pharmacokinetic analyses. With the 200/100&nbsp;mg daily dose regimen at an infusion rate of 1.1&nbsp;mg/min, the steady state C<sub>max </sub>and trough concentrations (C<sub>min</sub>) could reach approximately 7 and 3&nbsp;mg/l, respectively, with an average steady state AUC of approximately 110&nbsp;mg&times;h/l.</p><p>&nbsp;</p><p><em>Weight</em></p><p>Although weight was identified as a source of variability in clearance in the population pharmacokinetic analysis, weight has little clinical relevance on the pharmacokinetics of anidulafungin.</p><p>&nbsp;</p><p><em>Gender</em></p><p>Plasma concentrations of anidulafungin in healthy men and women were similar. In multiple-dose patient studies, drug clearance was slightly faster (approximately 22%) in men.&nbsp;</p><p>&nbsp;</p><p><em>Elderly</em></p><p>The population pharmacokinetic analysis showed that median clearance differed slightly between the elderly group (patients &ge; 65, median CL = 1.07&nbsp;l/h) and the non-elderly group (patients &lt; 65, median CL = 1.22&nbsp;l/h), however the range of clearance was similar.</p><p>&nbsp;</p><p><em>Ethnicity</em></p><p>Anidulafungin pharmacokinetics were similar among Caucasians, Blacks, Asians, and Hispanics.&nbsp;</p><p>&nbsp;</p><p><em>HIV positivity</em></p><p>Dosage adjustments are not required based on HIV positivity, irrespective of concomitant anti-retroviral therapy.</p><p>&nbsp;</p><p><em>Hepatic insufficiency </em></p><p>Anidulafungin is not hepatically metabolised. Anidulafungin pharmacokinetics were examined in subjects with Child-Pugh class A, B or C hepatic insufficiency. Anidulafungin concentrations were not increased in subjects with any degree of hepatic insufficiency. Although a slight decrease in AUC was observed in patients with Child-Pugh C hepatic insufficiency, the decrease was within the range of population estimates noted for healthy subjects.&nbsp;</p><p>&nbsp;</p><p><em>Renal insufficiency</em></p><p>Anidulafungin has negligible renal clearance (&lt;1%). In a clinical study of subjects with mild, moderate, severe or end stage (dialysis-dependent) renal insufficiency, anidulafungin pharmacokinetics were similar to those observed in subjects with normal renal function. Anidulafungin is not dialysable and may be administered without regard to the timing of hemodialysis.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The pharmacokinetics of anidulafungin after at least 5 daily doses were investigated in 24 immunocompromised paediatric (2 to 11 years old) and adolescent (12 to 17 years old) patients with neutropenia. Steady state was achieved on the first day after a loading dose (twice the maintenance dose), and steady state C<sub>max</sub> and AUC<sub>ss</sub> increase in a dose-proportional manner. Systemic exposure following daily maintenance dose of 0.75 and 1.5&nbsp;mg/kg/day in this population were comparable to those observed in adults following 50 and 100&nbsp;mg/day, respectively. Both regimens were well-tolerated by these patients.</p><p>&nbsp;</p><p>The pharmacokinetics of anidulafungin was investigated in 66 paediatric patients (1 month to &lt;&nbsp;18&nbsp;years) with ICC in a prospective, open-label, non-comparative paediatric study following administration of 3.0&nbsp;mg/kg loading dose and 1.5&nbsp;mg/kg/day maintenance dose (see section 5.1). Based on population pharmacokinetic analysis of combined data from adult and paediatric patients with ICC, the mean exposure parameters (AUC<sub>0-24,ss </sub>and C<sub>min,ss</sub>) at steady state in the overall paediatric patients across age groups (1 month to &lt;&nbsp;2 years, 2 to &lt;&nbsp;5 years, and 5 to &lt;&nbsp;18 years) were comparable to those in adults receiving 200&nbsp;mg loading dose and 100&nbsp;mg/day maintenance dose. Body weight adjusted CL (L/h/kg) and volume of distribution at steady state (L/kg) were similar across the age groups.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General pharmacokinetic characteristics </u></p><p><u>&nbsp;</u></p><p>The pharmacokinetics of anidulafungin have been characterised in healthy subjects, special populations and patients. A low intersubject variability in systemic exposure (coefficient of variation ~25%) was observed. The steady state was achieved on the first day after a loading dose (twice the daily maintenance dose).</p><p>&nbsp;</p><p><u>Distribution</u></p><p><br />The pharmacokinetics of anidulafungin are characterised by a rapid distribution half-life (0.5-1 hour) and a volume of distribution, 30-50&nbsp;l, which is similar to total body fluid volume. Anidulafungin is extensively bound (&gt;99%) to human plasma proteins. No specific tissue distribution studies of anidulafungin have been done in humans. Therefore, no information is available about the penetration of anidulafungin into the cerebrospinal fluid (CSF) and/or across the blood-brain barrier.&nbsp;</p><p>&nbsp;</p><p><u>Biotransformation </u></p><p><u>&nbsp;</u></p><p>Hepatic metabolism of anidulafungin has not been observed. Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 isoenzymes. It is unlikely that anidulafungin will have clinically relevant effects on the metabolism of drugs metabolised by cytochrome P450 isoenzymes.</p><p>&nbsp;</p><p>Anidulafungin undergoes slow chemical degradation at physiologic temperature and pH to a ring-opened peptide that lacks antifungal activity. The <em>in vitro</em> degradation half-life of anidulafungin under physiologic conditions is approximately 24 hours. <em>In vivo</em>, the ring-opened product is subsequently converted to peptidic degradants and eliminated mainly through biliary excretion.</p><p>&nbsp;</p><p><u>Elimination</u></p><p><br />The clearance of anidulafungin is about 1&nbsp;l/h. Anidulafungin has a predominant elimination half-life of approximately 24 hours that characterizes the majority of the plasma concentration-time profile, and a terminal half-life of 40-50 hours that characterises the terminal elimination phase of the profile.</p><p>&nbsp;</p><p>In a single-dose clinical study, radiolabeled (<sup>14</sup>C)<strong> </strong>anidulafungin (~88&nbsp;mg) was administered to healthy subjects. Approximately 30% of the administered radioactive dose was eliminated in the faeces over 9 days, of which less than 10% was intact drug. Less than 1% of the administered radioactive dose was excreted in the urine, indicating negligible renal clearance. Anidulafungin concentrations fell below the lower limits of quantitation 6 days post-dose. Negligible amounts of drug-derived radioactivity were recovered in blood, urine, and faeces 8 weeks post-dose.</p><p>&nbsp;</p><p><u>Linearity</u></p><p><br />Anidulafungin displays linear pharmacokinetics across a wide range of once daily doses (15-130&nbsp;mg).</p><p>&nbsp;</p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p><em>Patients with fungal infections&nbsp; </em></p><p>The pharmacokinetics of anidulafungin in patients with fungal infections are similar to those observed in healthy subjects based on population pharmacokinetic analyses. With the 200/100&nbsp;mg daily dose regimen at an infusion rate of 1.1&nbsp;mg/min, the steady state C<sub>max </sub>and trough concentrations (C<sub>min</sub>) could reach approximately 7 and 3&nbsp;mg/l, respectively, with an average steady state AUC of approximately 110&nbsp;mg&times;h/l.</p><p>&nbsp;</p><p><em>Weight</em></p><p>Although weight was identified as a source of variability in clearance in the population pharmacokinetic analysis, weight has little clinical relevance on the pharmacokinetics of anidulafungin.</p><p>&nbsp;</p><p><em>Gender</em></p><p>Plasma concentrations of anidulafungin in healthy men and women were similar. In multiple-dose patient studies, drug clearance was slightly faster (approximately 22%) in men.&nbsp;</p><p>&nbsp;</p><p><em>Elderly</em></p><p>The population pharmacokinetic analysis showed that median clearance differed slightly between the elderly group (patients &ge; 65, median CL = 1.07&nbsp;l/h) and the non-elderly group (patients &lt; 65, median CL = 1.22&nbsp;l/h), however the range of clearance was similar.</p><p>&nbsp;</p><p><em>Ethnicity</em></p><p>Anidulafungin pharmacokinetics were similar among Caucasians, Blacks, Asians, and Hispanics.&nbsp;</p><p>&nbsp;</p><p><em>HIV positivity</em></p><p>Dosage adjustments are not required based on HIV positivity, irrespective of concomitant anti-retroviral therapy.</p><p>&nbsp;</p><p><em>Hepatic insufficiency </em></p><p>Anidulafungin is not hepatically metabolised. Anidulafungin pharmacokinetics were examined in subjects with Child-Pugh class A, B or C hepatic insufficiency. Anidulafungin concentrations were not increased in subjects with any degree of hepatic insufficiency. Although a slight decrease in AUC was observed in patients with Child-Pugh C hepatic insufficiency, the decrease was within the range of population estimates noted for healthy subjects.&nbsp;</p><p>&nbsp;</p><p><em>Renal insufficiency</em></p><p>Anidulafungin has negligible renal clearance (&lt;1%). In a clinical study of subjects with mild, moderate, severe or end stage (dialysis-dependent) renal insufficiency, anidulafungin pharmacokinetics were similar to those observed in subjects with normal renal function. Anidulafungin is not dialysable and may be administered without regard to the timing of hemodialysis.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The pharmacokinetics of anidulafungin after at least 5 daily doses were investigated in 24 immunocompromised paediatric (2 to 11 years old) and adolescent (12 to 17 years old) patients with neutropenia. Steady state was achieved on the first day after a loading dose (twice the maintenance dose), and steady state C<sub>max</sub> and AUC<sub>ss</sub> increase in a dose-proportional manner. Systemic exposure following daily maintenance dose of 0.75 and 1.5&nbsp;mg/kg/day in this population were comparable to those observed in adults following 50 and 100&nbsp;mg/day, respectively. Both regimens were well-tolerated by these patients.</p><p>&nbsp;</p><p>The pharmacokinetics of anidulafungin was investigated in 66 paediatric patients (1 month to &lt;&nbsp;18&nbsp;years) with ICC in a prospective, open-label, non-comparative paediatric study following administration of 3.0&nbsp;mg/kg loading dose and 1.5&nbsp;mg/kg/day maintenance dose (see section 5.1). Based on population pharmacokinetic analysis of combined data from adult and paediatric patients with ICC, the mean exposure parameters (AUC<sub>0-24,ss </sub>and C<sub>min,ss</sub>) at steady state in the overall paediatric patients across age groups (1 month to &lt;&nbsp;2 years, 2 to &lt;&nbsp;5 years, and 5 to &lt;&nbsp;18 years) were comparable to those in adults receiving 200&nbsp;mg loading dose and 100&nbsp;mg/day maintenance dose. Body weight adjusted CL (L/h/kg) and volume of distribution at steady state (L/kg) were similar across the age groups.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In 3 month studies, evidence of liver toxicity, including elevated enzymes and morphologic alterations,&nbsp;was observed in both rats and monkeys at doses 4- to 6-fold higher than the anticipated clinical therapeutic exposure. <em>In vitro</em> and <em>in vivo</em> genotoxicity studies with anidulafungin provided no evidence of genotoxic potential. Long‑term studies in animals have not been conducted to evaluate the carcinogenic potential of anidulafungin.</p><p>&nbsp;</p><p>Administration of anidulafungin to rats did not indicate any effects on reproduction, including male and female fertility.</p><p>&nbsp;</p><p>Anidulafungin crossed the placental barrier in rats and was detected in foetal plasma.</p><p>&nbsp;</p><p>Embryo-foetal development studies were conducted with doses between 0.2- and 2-fold (rats) and between 1- and 4-fold (rabbits) the proposed therapeutic maintenance dose of 100 mg/day. Anidulafungin did not produce any drug-related developmental toxicity in rats at the highest dose tested. Developmental effects observed in rabbits (slightly reduced foetal weights) occurred only at the highest dose tested, a dose that also produced maternal toxicity.</p><p>&nbsp;</p><p>The concentration of anidulafungin in the brain was low (brain to plasma ratio of approximately 0.2) in uninfected adult and neonatal rats after a single dose. However, brain concentrations increased in uninfected neonatal rats after five daily doses (brain to plasma ratio of approximately 0.7). In multiple dose studies in rabbits with disseminated candidiasis and in mice with central nervous system (CNS) <em>Candida</em> infection, anidulafungin has been shown to reduce fungal burden in the brain. Results of pharmacokinetic-pharmacodynamic studies in rabbit models of disseminated candidiasis and hematogenous <em>Candida</em> meningoencephalitis indicated that higher doses of anidulafungin were needed to optimally treat infections of CNS tissues relative to non-CNS tissues (see section 4.4).</p><p><strong>&nbsp;</strong></p><p>Rats were dosed with anidulafungin at three dose levels and anaesthetised within one hour using a combination of ketamine and xylazine. Rats in the high dose group experienced infusion-related reactions that were exacerbated by anaesthesia. Some rats in the mid dose group experienced similar reactions but only after administration of anaesthesia. There were no adverse reactions in the low-dose animals in the presence or absence of anaesthesia, and no infusion-related reactions in the mid-dose group in the absence of anaesthesia. &nbsp;</p><p><strong>&nbsp;</strong></p><p>Studies conducted in juvenile rats did not indicate a greater susceptibility to anidulafungin hepatotoxicity compared to adult animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fructose</p><p>Mannitol</p><p>Polysorbate 80</p><p>Tartaric acid</p><p>Sodium hydroxide (for pH-adjustment)</p><p>Hydrochloric acid (for pH-adjustment)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products or electrolytes except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Keep out of the sight and reach of children.

Shelf life: 36 months.
Do not use Ecalta after the expiry date which is stated on the carton / Bottle / Vial label after EXP. 

The expiry date refers to the last day of that month.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

Excursions for 96 hours up to 25ºC are permitted, and the powder can be returned to refrigerated storage.

Reconstituted solution

The (reconstituted) infusion solution should not be frozen.
The infusion solution should be stored in a refrigerator (2°C - 8°C). 
The reconstituted solution may be stored at up to 25°C for up to 24 hours.

Chemical and physical in-use stability of the reconstituted solution has been demonstrated for 24 hours at 25ºC.

From a microbiological point of view, following good aseptic practices, the reconstituted solution can be utilized for up to 24 hours when stored at 25ºC.

Infusion solution 

The (reconstituted) infusion solution should not be frozen.
The infusion solution should be stored in a refrigerator (2°C - 8°C).
The infusion solution may be stored at 25ºC for 48 hours. Do not freeze.

Chemical and physical in-use stability of the infusion solution has been demonstrated for 48 hours at 25ºC.

From a microbiological point of view, following good aseptic practices, the infusion solution can be utilized for up to 48 hours from preparation when stored at 25ºC.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze.</p><p>For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>30&nbsp;mL Type 1 glass vial with an elastomeric stopper, and a flip-off seal.</p><p>Pack size of 1 vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no special requirements for disposal.</p><p>&nbsp;</p><p>ECALTA must be reconstituted with water for injection and subsequently diluted with ONLY sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection or 50&nbsp;mg/mL (5%) glucose for infusion. The compatibility of reconstituted ECALTA with intravenous substances, additives, or medicines other than 9&nbsp;mg/mL (0.9%) sodium chloride for infusion or 50&nbsp;mg/mL (5%) glucose for infusion has not been established. The infusion solution must not be frozen.</p><p>&nbsp;</p><p><u>Reconstitution</u></p><p><u>&nbsp;</u></p><p>Aseptically reconstitute each vial with 30 mL water for injection to provide a concentration of 3.33&nbsp;mg/mL. The reconstitution time can be up to 5 mins. After subsequent dilution, the solution is to be discarded if particulate matter or discoloration is identified.</p><p>&nbsp;</p><p><u>Dilution and infusion</u></p><p><u>&nbsp;</u></p><p><strong>Parenteral medicinal products </strong><strong>should be inspected visually for particulate matter and discolouration prior to administration</strong><strong>, whenever solution and container permit</strong><strong>. If particulate matter or discolouration is identified, discard the solution. </strong></p><p><u>&nbsp;</u></p><p><u>Adult Patients</u></p><p><u>&nbsp;</u></p><p>Aseptically transfer the contents of the reconstituted vial(s) into an intravenous bag (or bottle) containing either 9&nbsp;mg/mL (0.9%) sodium chloride for infusion or 50&nbsp;mg/mL (5%) glucose for infusion to obtain the appropriate ECALTA &nbsp;concentration. The table below provides the dilution to a concentration of 0.77 mg/ml for the final infusion solution and infusion instructions for each dose.</p><p>&nbsp;</p><p><u>Dilution requirements for ECALTA administration</u></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><tbody><tr><td style="vertical-align:top"><p><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>Number</strong></p><p><strong>of vials of powder </strong></p></td><td style="vertical-align:top"><p><strong>Total reconstituted volume</strong></p></td><td style="vertical-align:top"><p><strong>Infusion volume <sup>A</sup></strong></p></td><td style="vertical-align:top"><p><strong>Total infusion volume<sup>B</sup></strong></p></td><td style="vertical-align:top"><p><strong>Rate of infusion</strong></p></td><td style="vertical-align:top"><p><strong>Minimum duration</strong><strong> of infusion</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>100&nbsp;mg</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>30&nbsp;mL</p></td><td style="vertical-align:top"><p>100&nbsp;mL</p></td><td style="vertical-align:top"><p>130&nbsp;mL</p></td><td style="vertical-align:top"><p>1.4&nbsp;mL/<br />min or 84 mL/hour</p></td><td style="vertical-align:top"><p>90 min</p></td></tr><tr><td style="vertical-align:top"><p>200&nbsp;mg</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>60&nbsp;mL</p></td><td style="vertical-align:top"><p>200&nbsp;mL</p></td><td style="vertical-align:top"><p>260&nbsp;mL</p></td><td style="vertical-align:top"><p>1.4&nbsp;mL<br />/min or 84 mL/ hour</p></td><td style="vertical-align:top"><p>180 min</p></td></tr></tbody></table><p><sup>A</sup> Either 9&nbsp;mg/mL (0.9%) sodium chloride for infusion or 50&nbsp;mg/mL (5%) glucose for infusion.&nbsp;</p><p><sup>B</sup> Infusion solution concentration is 0.77&nbsp;mg/mL</p><p>&nbsp;</p><p>The rate of infusion should not exceed 1.1&nbsp;mg/min (equivalent to 1.4&nbsp;mL/min or 84 mL/hour when reconstituted and diluted per instructions) (see sections 4.2, 4.4 and 4.8).</p><p>&nbsp;</p><p><u>Paediatric Patients</u></p><p>&nbsp;</p><p>For paediatric patients aged 1 month to &lt;&nbsp;18&nbsp;years, the volume of infusion solution required to deliver the dose will vary depending on the weight of the patient. The reconstituted solution must be further diluted to a concentration of 0.77 mg/mL for the final infusion solution. A programmable syringe or infusion pump is recommended. <strong>The rate of infusion should not exceed 1.1 mg/minute (equivalent to 1.4 mL/minute or 84 mL/hour when reconstituted and diluted per instructions) </strong>(see sections 4.2 and 4.4).&nbsp;</p><p>&nbsp;</p><p>1. Calculate patient dose and reconstitute vial(s) required according to &nbsp;reconstitution instructions to provide a concentration of 3.33 mg/mL (see sections 2, and 4.2)</p><p>&nbsp;</p><p>2.&nbsp;&nbsp; Calculate the volume (mL) of reconstituted anidulafungin required: <em>&nbsp;</em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot; <u>Volume of anidulafungin (mL)</u> = Dose of anidulafungin (mg) &cedil; 3.33 mg/mL</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.&nbsp;&nbsp; Calculate the total volume of dosing solution (mL) required to provide a final concentration of 0.77&nbsp;mg/mL:</p><p><em>&nbsp;</em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot; <u>Total volume of dosing solution (mL)</u> = Dose of anidulafungin (mg) &divide; 0.77&nbsp;mg/mL</p><p><em>&nbsp;</em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.&nbsp;&nbsp; Calculate the volume of diluent [5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (normal saline)] required to prepare the dosing solution:</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot; <u>Volume of diluent (mL)</u> = Total volume of dosing solution (mL) &ndash; Volume of anidulafungin (mL)</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.&nbsp;&nbsp; Aseptically transfer the required volumes (mL) of anidulafungin and 5% Dextrose Injection, USP or 0.9%&nbsp;Sodium Chloride Injection, USP (normal saline) into an infusion syringe or IV infusion bag needed for administration.&nbsp;</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER

Pfizer Manufacturing Belgium NV, Belgium


Manufacturer

Pharmacia Upjohn Company LLC, United States.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>